JPWO2020185755A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020185755A5 JPWO2020185755A5 JP2021552136A JP2021552136A JPWO2020185755A5 JP WO2020185755 A5 JPWO2020185755 A5 JP WO2020185755A5 JP 2021552136 A JP2021552136 A JP 2021552136A JP 2021552136 A JP2021552136 A JP 2021552136A JP WO2020185755 A5 JPWO2020185755 A5 JP WO2020185755A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- stereoisomer
- solvate
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 150000003839 salts Chemical class 0.000 claims 37
- 239000012453 solvate Substances 0.000 claims 37
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 20
- -1 C 1 -C 6 aminoalkyl Chemical group 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 13
- 229910052805 deuterium Inorganic materials 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims 3
- 125000005345 deuteroalkyl group Chemical group 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 102000002227 Interferon Type I Human genes 0.000 claims 1
- 108010014726 Interferon Type I Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816698P | 2019-03-11 | 2019-03-11 | |
| US62/816,698 | 2019-03-11 | ||
| US201962835376P | 2019-04-17 | 2019-04-17 | |
| US62/835,376 | 2019-04-17 | ||
| US201962877741P | 2019-07-23 | 2019-07-23 | |
| US62/877,741 | 2019-07-23 | ||
| US201962931119P | 2019-11-05 | 2019-11-05 | |
| US62/931,119 | 2019-11-05 | ||
| PCT/US2020/021850 WO2020185755A1 (en) | 2019-03-11 | 2020-03-10 | Tyk2 inhibitors and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022524974A JP2022524974A (ja) | 2022-05-11 |
| JP2022524974A5 JP2022524974A5 (https=) | 2023-03-20 |
| JPWO2020185755A5 true JPWO2020185755A5 (https=) | 2023-03-20 |
| JP7586829B2 JP7586829B2 (ja) | 2024-11-19 |
Family
ID=72427699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552136A Active JP7586829B2 (ja) | 2019-03-11 | 2020-03-10 | Ｔｙｋ２阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220177486A1 (https=) |
| EP (1) | EP3938369A4 (https=) |
| JP (1) | JP7586829B2 (https=) |
| KR (1) | KR102899985B1 (https=) |
| CN (1) | CN113811534B (https=) |
| AU (1) | AU2020239026B2 (https=) |
| BR (1) | BR112021017996A2 (https=) |
| CA (1) | CA3132632A1 (https=) |
| IL (1) | IL286248B2 (https=) |
| WO (1) | WO2020185755A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| AU2020247990A1 (en) * | 2019-03-26 | 2021-11-11 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| US12410191B2 (en) | 2019-05-21 | 2025-09-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Macrolide derivatives, preparation method and application thereof |
| KR102938141B1 (ko) | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
| AU2021345181A1 (en) * | 2020-09-16 | 2023-05-04 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| WO2022117090A1 (zh) * | 2020-12-03 | 2022-06-09 | 成都科岭源医药技术有限公司 | 一种多环化合物及其制备方法和用途 |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| JP2025509596A (ja) * | 2022-03-16 | 2025-04-11 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| WO2023178235A1 (en) * | 2022-03-16 | 2023-09-21 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
| WO2024199479A1 (zh) * | 2023-03-31 | 2024-10-03 | 北京普祺医药科技股份有限公司 | 一种大环化合物、药物组合物及其用途 |
| WO2024222807A1 (en) * | 2023-04-27 | 2024-10-31 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Novel macrocyclic heteroaryl derivatives as kinase inhibitors |
| WO2025194074A1 (en) * | 2024-03-15 | 2025-09-18 | Neuron23, Inc. | Kinase modulators and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| EP3080131B1 (en) * | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| PL3636649T3 (pl) * | 2014-01-24 | 2024-05-06 | Turning Point Therapeutics, Inc. | Diaryle makrocykliczne jako modulatory kinaz białkowych |
| ES2864839T3 (es) * | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| JOP20190092A1 (ar) * | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) * | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US11286264B2 (en) * | 2017-07-28 | 2022-03-29 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
| KR102717819B1 (ko) * | 2017-07-28 | 2024-10-14 | 다케다 야쿠힌 고교 가부시키가이샤 | Tyk2 억제제 및 이의 용도 |
| CN109053682B (zh) * | 2018-07-27 | 2020-10-27 | 东南大学 | 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法 |
| AU2020247990A1 (en) * | 2019-03-26 | 2021-11-11 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| KR102938141B1 (ko) * | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
-
2020
- 2020-03-10 CA CA3132632A patent/CA3132632A1/en active Pending
- 2020-03-10 IL IL286248A patent/IL286248B2/en unknown
- 2020-03-10 CN CN202080034800.9A patent/CN113811534B/zh active Active
- 2020-03-10 KR KR1020217032541A patent/KR102899985B1/ko active Active
- 2020-03-10 BR BR112021017996A patent/BR112021017996A2/pt unknown
- 2020-03-10 WO PCT/US2020/021850 patent/WO2020185755A1/en not_active Ceased
- 2020-03-10 US US17/438,329 patent/US20220177486A1/en not_active Abandoned
- 2020-03-10 JP JP2021552136A patent/JP7586829B2/ja active Active
- 2020-03-10 AU AU2020239026A patent/AU2020239026B2/en active Active
- 2020-03-10 EP EP20769748.3A patent/EP3938369A4/en active Pending
-
2025
- 2025-05-20 US US19/213,418 patent/US20250276977A1/en active Pending